trending Market Intelligence /marketintelligence/en/news-insights/trending/m65sxoxame03mdbbqr5rnq2 content esgSubNav
In This List

Agios CEO to step down; will be replaced by former Celgene president/COO

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Agios CEO to step down; will be replaced by former Celgene president/COO

Agios Pharmaceuticals Inc. said David Schenkein will step down as CEO on Feb. 1, 2019 and become executive chairman of the board.

Schenkein has served as CEO of the Cambridge, Mass.-based company since 2009 and oversaw the U.S. approval of two cancer medicines.

Jacqualyn Fouse, who joined Agios' board in December 2017, will succeed Schenkein as CEO. She will remain on the board of directors.

Fouse previously worked as president and COO of Summit, N.J.-based biopharmaceutical company Celgene Corp.

Further, Agios Chairman John Maraganore will become a director when Schenkein becomes chairman.